Open AccessTedizolid as Step-Down Therapy following Daptomycin versus Continuation of Daptomycin against Enterococci and Methicillin- and Vancomycin-Resistant Staphylococcus aureus in a Rat Endocarditis Model
Author(s) -
Kavindra V. Singh,
César A. Arias,
Barbara E. Murray
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02303-19
Subject(s) - daptomycin , enterococcus faecium , enterococcus faecalis , medicine , vancomycin , staphylococcus aureus , gentamicin , endocarditis , enterococcus , microbiology and biotechnology , ceftriaxone , ampicillin , infective endocarditis , antibiotics , methicillin resistant staphylococcus aureus , bacteria , biology , genetics
Tedizolid (TZD) and daptomycin (DAP) were assessed in a rat endocarditis model against Enterococcus faecalis , Enterococcus faecium (resistant to vancomycin and ampicillin), and Staphylococcus aureus As a monotherapy, TZD for 5 days was not effective in a comparison with no-treatment controls, while DAP for 5 days was significantly effective against these bacteria. Step-down therapy (DAP for 3 days followed by TZD for 2 days) was as effective as DAP for 5 days and was comparable to 3 days of DAP plus ceftriaxone against all bacteria and to 3 days of DAP plus gentamicin against E. faecalis OG1RF.